MedTrace Logo

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

NCT05229341 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1450

Last updated 2026-02-23

No results posted yet for this study

Summary

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

Conditions

  • Thyroid Gland Carcinoma

Interventions

PROCEDURE

Diagnostic Procedure

Analysis via DDMS-2

OTHER

Electronic Health Record Review

Review of medical records

PROCEDURE

Needle Biopsy

Undergo needle biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • John H Yim · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-22
Primary Completion
2026-10-22
Completion
2026-10-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229341 on ClinicalTrials.gov